Genomed S.a. · NEWCONNECT:GEN
Genomed — Investor Presentation (September 2012)
18 slides from Genomed's investor presentation, September 2012
Slide 1: Genomed S.A. - September 2012
Genomed S.A. mm | E\Genomed «i= Semptember 2012
Slide 2: Marek Zagulski - Visit card
Marek Zagulski - Visit card http://scholar.google.com/citations?hl=en&user=eYpm38IAAAAJ
Slide 3: Management Board
Management Board Marek Zagulski, Ph.D. CEO, Co-founder and joint owner of the Company Graduated from the Faculty of Biology, University of Warsaw, in 1990; received a Ph.D. degree at the Institute of Biochemistry and Biophysics, Polish Academy of Sciences (PAS), in 1998; • 1998-1999 - postdoctoral t
Slide 4: Financial results - 2008-2011
Financial results - 2008-2011 5 000,00 4 000,00 3 000,00 2 000,00 1 000,00 k PLN - 2008 2009 2010 2011 -1 000,00 revenue income EBITDA profit
Slide 5: Financial results - forecasts of year 2007 and execution
Financial results - forecasts of year 2007 and execution Revenue EBITDA kPLN kPLN 5 000 4 500 800 4 000 600 3 500 3 000 400 Plan 2 500 Execution 200 Plan 2 000 Execution 1 500 0 1 000 2008 2009 2010 2011 500 -200 - -400 2008 2009 2010 2011 -600
Slide 6: Financial results – 2008-2012 PLN
Financial results – 2008-2012 PLN 7 000 000,00 6 000 000,00 5 000 000,00 4 000 000,00 3 000 000,00 2 000 000,00 1 000 000,00 0,00 -1 000 000,00 2008 2009 2010 2011 2012*plan Przychody ze sprzedaży 642 363,42 1 763 929,00 3 858 020,65 4 619 605,82 6 363 909,50 Wynik netto -619 915,48 -92 833,93 305 7
Slide 7: Month to month revenues 01.2008-06.2012 (PLN)
month to month revenues 01.2008-06.2012 (PLN) 800 000 700 000 600 000 500 000 400 000 300 000 200 000 100 000 0 Przychody-Plan Przychody-realizacja
Slide 8: Genomed S.A. shareholders
Genomed S.A. shareholders — TT TT TTT ETETEL_ Akcjonariat 1 MCI.BioVentures Fundusz Inwestycyjny Zamkniety Mi Marek Zaguiski W Anna Boguszewska — Chachulska @ Andrzej Patucha MB lwona Wach 1 Andrzej Migdalski @ Pazostate akcje serii A Akcje seri B — loé —_iodé gloséw. udzial w kapitale vlocath na ak
Slide 9: Genom23.pl – portal to your genome
Genom23.pl – portal to your genome
Slide 10: MiSeq – Genomic class Sequencer - Human Genome in 36 hours
MiSeq – Genomic class Sequencer - Human Genome in 36 hours
Slide 11: Genomed's Fluidigm – nanofluidics system
Genomed’s Fluidigm – nanofluidics system
Slide 12: Microfluidic technology – gate to multiamplicon diagnostics
Microfluidic technology – gate to multiamplicon diagnostics
Slide 13: Bioinformatic Team – preparing tailor-made software
Bioinformatic Team – preparing tailor-made software
Slide 14: Genomed Tree – Business Model?
Genomed Tree – Business Model?
Slide 15: Genomed websites
Genomed websites About Us | Info Download re: ] DNA SEQUENCING ] OLIGONUCLEOTIDES, Synt SEQUENCE | Analysis | E-STORE I HOM. 12D |TEMPLATE metobign Beituce ©G@Genomed ts i Contact mmm | Login| Repsvaton Investor Relations Press | My Account | % —_— Looe ‘ i } ze GENERAL INFORMATION Welcome to Genome
Slide 16: SWOT analysis - Threats
SWOT analysis - Threats National Health Fund (NFZ) Lack of society education including eco-terrorism, GMO hysteria Lack of true Biotech Centers Lack of qualified staff - collapsed education system Slow data transmission Insufficient data storage capacity EU help - administrative problems with fundin
Slide 17: Pfizer facility in Sandwich, Kent closed in 2011
Pfizer facility in Sandwich, Kent closed in 2011 The place where Viagra was born Reason: problems with the scientific team management
Slide 18: Genomed team (2012)
Genomed team (2012) Genomed is the only company in Poland that offers Next Generation Sequencing services. We are unique in offering full data analysis. www.genomed.pl www.genomed.eu e-mail: info@genomed.pl